JAK2 and neoplasm: Moreover, exploring the potential synergistic effect of selective JAK2 inhibition in other tumor models, including solid tumors, would be attractive because CAR-T cell therapy for solid tumors is challenging and multiple efforts are being made to improve CAR-T cell immune exhaustion in the tumor microenvironment.